amc303

AMC303 is a first-in-class synthetic cyclic peptide that acts as a highly specific inhibitor of CD44v6, a splice variant of the CD44 family of transmembrane glycoproteins. CD44v6 functions as an essential co-receptor for several receptor tyrosine kinases (RTKs), including VEGFR-2, c-MET, and RON. By binding to CD44v6, AMC303 blocks signaling through these RTKs and thereby interferes with key processes in tumor progression such as epithelial-mesenchymal transition (EMT), cell migration, invasion, angiogenesis, and metastasis formation. Preclinical studies have demonstrated strong anti-tumor and anti-metastatic effects across various epithelial cancers. The drug is being developed primarily for advanced and metastatic epithelial tumors—including esophageal squamous cell carcinoma—and has shown potential in other solid tumors such as pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer, and lung cancer. Clinical development has reached Phase 2 for esophageal squamous cell carcinoma[1][2][3][4][5][6][8].

Other names

AMC 303AMC303AMC-303HP 558HP558HP-558